【摘要】 背景与目的 表皮生长因子受体酪氨酸激酶抑制剂（epidermal growth factor receptor tyrosine kinase inhibitor, EGFR-TKI）治疗非小细胞肺癌（non-small cell lung cancer, NSCLC）有效的临床预测指标包括：女性、亚裔、 
group and 2-4 group, between more than 4 cycles of chemotherapy and 1-4 cycles, between PFS of chemotherapy >6 months group and ≤6 months group, however, ECOG 0-1 group and more than 4 cycles of chemotherapy or PFS of chemotherapy >6 months group seemed to have longer median PFS (15 months vs 10 months; 16 months vs 12 months; 14months vs 12 months). Compared with no skin rash and grade 0-I rash group, the patients with rash or grade ≥II rash had longer median PFS (16 months vs 13 months, P=0.171; 19 months vs 11 months, P=0.085). The median PFS was not related with sex, smoking index, pathological types, metastatic sites except bone, treatment strategy, etc (P>0.05). Conclusion For gefitinib treatment, longer median PFS is likely to be obtained in patients with >70 years old, earlier clinical stage (IIIb), non-bone metastasis.
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